Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1968 1
1970 1
1971 1
1972 2
1974 2
1977 1
1979 1
1980 1
1981 1
1984 1
1985 1
1987 1
1988 1
1992 1
1994 3
1997 2
1998 2
1999 1
2001 5
2002 2
2003 1
2005 1
2006 1
2007 4
2009 3
2010 1
2011 3
2012 1
2013 2
2014 2
2015 3
2016 1
2017 2
2018 2
2019 13
2020 9
2021 12
2022 4
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

95 results

Results by year

Filters applied: . Clear all
Page 1
Therapeutic potential of lefamulin in the treatment of community-acquired pneumonia.
Perry W, Golan Y. Perry W, et al. Future Microbiol. 2019 Jul;14:927-939. doi: 10.2217/fmb-2019-0027. Epub 2019 Jul 23. Future Microbiol. 2019. PMID: 31333062 Review.
Despite the increasing availability of antibiotics with activity against pathogens that cause community-acquired pneumonia (CAP), CAP remains a major cause of morbidity, hospital admissions and re-admissions, and mortality. ...
Despite the increasing availability of antibiotics with activity against pathogens that cause community-acquired pneumonia (CAP), CAP …
Clinical Pharmacokinetics and Pharmacodynamics of Lefamulin.
McCarthy MW. McCarthy MW. Clin Pharmacokinet. 2021 Nov;60(11):1387-1394. doi: 10.1007/s40262-021-01056-4. Epub 2021 Jul 13. Clin Pharmacokinet. 2021. PMID: 34254252 Review.
Lefamulin (Xenleta) has been approved by the US FDA for the treatment of community-acquired bacterial pneumonia (CABP). It may be taken intravenously or orally and has activity against a broad range of pulmonary pathogens, including Streptococcus pneumoniae, Haemoph …
Lefamulin (Xenleta) has been approved by the US FDA for the treatment of community-acquired bacterial pneumonia (CABP). It may be tak …
A plain language summary of how lefamulin alone can be used to treat pneumonia caught outside of the hospital due to common bacterial causes, including drug-resistant bacteria.
Paukner S, Moran GJ, Sandrock C, File TM Jr, Vidal JE, Waites KB, Gelone SP, Yu K. Paukner S, et al. Future Microbiol. 2022 Apr;17(6):397-410. doi: 10.2217/fmb-2021-0276. Epub 2022 Mar 14. Future Microbiol. 2022. PMID: 35285291 Free PMC article. Review.
WHAT IS THIS SUMMARY ABOUT? Bacterial pneumonia is an infection of the lung caused by bacteria that is potentially deadly, costly, and affects millions of people worldwide every year. ...Therefore, new antibiotics that work differently are needed to treat bacterial pneu
WHAT IS THIS SUMMARY ABOUT? Bacterial pneumonia is an infection of the lung caused by bacteria that is potentially deadly, costly, an …
Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia.
Watkins RR, File TM. Watkins RR, et al. Clin Infect Dis. 2020 Dec 17;71(10):2757-2762. doi: 10.1093/cid/ciaa336. Clin Infect Dis. 2020. PMID: 32221520 Review.
Community-acquired bacterial pneumonia (CABP) remains a significant cause of morbidity and mortality worldwide. ...
Community-acquired bacterial pneumonia (CABP) remains a significant cause of morbidity and mortality worldwide. ...
An overview of lefamulin for the treatment of community acquired bacterial pneumonia.
Falcó V, Burgos J, Almirante B. Falcó V, et al. Expert Opin Pharmacother. 2020 Apr;21(6):629-636. doi: 10.1080/14656566.2020.1714592. Epub 2020 Jan 20. Expert Opin Pharmacother. 2020. PMID: 31958020 Review.
INTRODUCTION: Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, including atypical pathogens, that cause community-acquired pneumonia (CAP). AREAS COVERED: This article reviews the spectrum of activi …
INTRODUCTION: Lefamulin is a novel antibiotic that belongs to the pleuromutilin class with excellent activity against all microorganisms, in …
Lefamulin: The First Systemic Pleuromutilin Antibiotic.
Chahine EB, Sucher AJ. Chahine EB, et al. Ann Pharmacother. 2020 Dec;54(12):1203-1214. doi: 10.1177/1060028020932521. Epub 2020 Jun 4. Ann Pharmacother. 2020. PMID: 32493034 Review.
DATA SYNTHESIS: Lefamulin is a pleuromutilin antibiotic with activity against Staphylococcus aureus, Streptococcus pneumoniae, and atypical bacteria. Lefamulin, given at the dose of 150 mg intravenously or 600 mg orally on an empty stomach every 12 hours for 5 to 7 days, w …
DATA SYNTHESIS: Lefamulin is a pleuromutilin antibiotic with activity against Staphylococcus aureus, Streptococcus pneumoniae, and at …
Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia.
Lee YR, Jacobs KL. Lee YR, et al. Drugs. 2019 Nov;79(17):1867-1876. doi: 10.1007/s40265-019-01219-5. Drugs. 2019. PMID: 31705486 Review.
Lefamulin (BC-3781) is the first systemic pleuromutilin antibiotic found to be safe and effective in the treatment of community-acquired bacterial pneumonia (CABP) in humans. This novel antibiotic was developed to combat the increasing incidence of bacterial resistance to …
Lefamulin (BC-3781) is the first systemic pleuromutilin antibiotic found to be safe and effective in the treatment of community-acquired bac …
A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin.
Wang H, Charles CV. Wang H, et al. Sr Care Pharm. 2020 Aug 1;35(8):349-354. doi: 10.4140/TCP.n.2020.349. Sr Care Pharm. 2020. PMID: 32718391 Review.
Lefamulin is a novel systemic, semi-synthetic pleuromutilin class of antimicrobials that has been shown to be effective against common respiratory pathogens associated with community-acquired bacterial pneumonia (CABP). CABP, a common infection among older people, leads to …
Lefamulin is a novel systemic, semi-synthetic pleuromutilin class of antimicrobials that has been shown to be effective against common respi …
95 results